This trial is active, not recruiting.

Condition non-small cell lung cancer
Treatment no intervention methods
Sponsor ying cheng
Start date December 2015
End date March 2017
Trial size 3000 participants
Trial identifier NCT02620657, 11224


Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective retrospective
The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
no intervention methods
No intervention methods required for this study

Primary Outcomes

To investigate the proportion of advanced NSCLC patients who performed EGFR mutation test
time frame: 2014.01.01-2014.12.31

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Histological or cytological confirmed NSCLC; - Patients were diagnosed with advanced NSCLC from Jan 1st 2014 to Dec 31st 2014; - Researchers should collect the records of consecutive NSCLC patients in each site. Exclusion Criteria: - Any patients without NSCLC diagnosis; - Any patients which were diagnosed with advanced NSCLC before Jan 1st 2014 or after Dec 31st 2014.

Additional Information

Official title A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China
Principal investigator CHENG NA Ying, Dr.
Description Approximately 3000 advanced NSCLC patients will be recruited , and the medical information of recruited patients must be recorded in the hospital electronic system from Jan 1st 2014 to Dec 31st 2014 .The study will focus on the EGFR testing rate in adenocarcinoma patients,so the collecting data for non-adenocarcinoma patients will be controlled in less than 10% for each site.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Guangdong Association of Clinical Trials.